Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers

A method for treating solid cancers or blood cancers, comprising, administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising, as an active ingredient, a 1,2-naphthoquinone derivative compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 and R2 are each independently hydrogen, halogen, hydroxy, C1-C6 alkoxy, C1-C6 alkyl, C4-C10 aryl, C4-C10 aryloxy, C2-C10 heteroaryl, —NO2, —NR′1R′2, —NR′1(CO(O)R′2), —NR′1(C(O)NR′1R′2), —CO(O)R′1, —C(O)NR′1R′2, —CN, —SO(O)R′1, —SO(O)NR′1R′2, —NR′1(SO(O)R′2), —CSNR′1R′2, or R1 and R2 taken together form a cyclic structure of C4-C10 aryl or a cyclic structure of C2-C10 heteroaryl, wherein R′1 and R′2 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, or C4-C10 aryl, C4-C10 aryloxy, C1-C8 heteroaryl, —(CR″1R″2)m—C4-C10 aryl, —(CR″1R″2)m—C4-C10 heteroaryl or NR″1R″2, the R″1 and R″2 are each independently hydrogen, C1-C3 alkyl, or R″1 and R″2 taken together form a cyclic structure of C4-C10 aryl;
• R3, R4 and R5 are each independently hydrogen, halogen, hydroxy, C1-C6 alkyl, C2-C10 alkene, C1-C6 alkoxy, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, C4-C10 aryl, C4-C10 aryloxy, C1-C8 heteroaryl, —(CR′5R′6)m—C4-C10 aryl, —(CR′5R′6)m—C4-C10 aryloxy, —(CR′5R′6)m—C1-C8 heteroaryl, —(CR′5R′6)m—NR′3R′4, —(CR′5R′6)m—C3-C8 heterocycloalkyl, —(CR′5R′6)m—OR′3, —(CR′5R′6)m(O)COR′3, —CO(O)R′3, —CONR′3R′4, —NR′3R′4, —NR′3(C(O)R′4), —SO(O)R′3, —SO(O)NR′3R′4, —NR′3(SO(O)R′4), —CSNR′3R′4, —CH2A where the compound of Chemical Formula 1 is “A”, or -A where the compound of Chemical Formula 1 is “A”, wherein the R′3 and R′4 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C10 aryl, —(CR′5R′6)m—C4-C10 aryl, —(CR′5R′6)m—C4-C10 aryloxy, —(CR′5R′6)m—C1-C10 heteroaryl, —CO(O)R″3, or, R′3 and R′4 taken together form a cyclic structure of C2-C10 heterocycloalkyl, or a cyclic structure of C1-C10 heteroaryl, the R′5 and R′6 are each independently hydrogen or C1-C3 alkyl, the R″3 is C1-C6 akyl;
• Q1 and Q2 are each independently CO, COR6, or COR7, when Q1 is CO and Q2 is CO, Q1 and Q2 form a single bond, when Q1 is COR6 and Q2 is COR7, Q1 and Q2 form a double bond;
• R6 and R7 are each independently hydrogen, C1-C10 alkoxy, C1-C6 alkyl, C4-C10 aryl, C4-C10 aryloxy, C2-C10 heteroaryl, —CO(O)R′7, —C(O)NR′7R′8, —SO(O)R′7, —SO(O)NR′7R′8, —SO3R′7, —PO3R′7, —CSNR′7R′8, or R6 and R7 taken together form a cyclic structure of C3-C10 heterocycloalkyl, or a cyclic structure of C3-C10 heteroaryl, the R′7 and R′8 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C10 aryl, C4-C10 aryloxy, C1-C8 heteroaryl, —(CR″4R″5)m′—C4-C10 aryl, the R″4 and R″5 are each independently hydrogen, C1-C3 alkoxy;
• m and m′ are each independently an integer of 1 to 4;
• the hetero atom is at least one selected from N, O and S;
• X1 to X4 are each independently CH or N(R″6);
• X5 is N, X6 is C, X7 is N, wherein R″6 is hydrogen or C1-C3 alkyl;
• in the Chemical Formula, the notation means a single bond or a double bond, the notation means that a single bond or a bond may not be formed, the notation means that the cyclic structure may be or may not be aromatic;
• and
• the substituted means being substituted with one or more substituents selected from the group consisting of hydroxy, halogen element, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkoxy, C1-C10 alkoxycarbonyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, C4-C10 aryl, and C2-C10 heteroaryl;
• wherein the blood cancer is selected from the group consisting of acute leukemia, chronic leukemia and drug-resistant chronic leukemia or refractory acute leukemia;
• the chronic leukemia is selected from the group consisting of chronic myelogenous leukemia or chronic lymphocytic leukemia;
• the acute leukemia is selected from the group consisting of acute myelogenous leukemia or acute lymphocytic leukemia;
• and
• the solid cancer is selected from the group consisting of lung cancer, uterine cancer, liver cancer and breast cancer.